Why Immunome, Inc.’s (IMNM) Stock Is Down 5.20%
As of Thursday, September 24, Immunome, Inc.’s IMNM share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Commentary & Analysis
Why Immunome, Inc.’s (IMNM) Stock Is Down 5.40%
As of Wednesday, September 23, Immunome, Inc.’s IMNM share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Michael Rose
Why Immunome, Inc.’s (IMNM) Stock Is Up 5.25%
As of Wednesday, September 02, Immunome, Inc.’s IMNM share price has surged by 5.25%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Immunome, Inc.’s (IMNM) Stock Is Up 5.39%
As of Tuesday, August 25, Immunome, Inc.’s IMNM share price has surged by 5.39%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Immunome, Inc.’s (IMNM) Stock Is Up 6.21%
As of Friday, August 21, Immunome, Inc.’s IMNM share price has surged by 6.21%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,220.4 | $242.6 | 56% |
|
| Shares Out (Mil) | 113.3 | 54.0 | 65% |
|
| Institutional Ownership | 98.9% | 93.1% | 83% |
|
| Float (Mil) | 108.7 | 41.4 | 62% |
|
| Beta | 2.12 | 0.95 | 93% |
|
| Avg Daily Volume (000s) | 1,320 | 633 | 74% |
|
| Price Change (52-week) |
39.5% | 50.0% | 81% |
|
| Growth | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (64.2%) | (10.1%) | 5% |
|
| EPS (5yr) | 14.3% | 15.8% | 55 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (11.9%) | (15.7%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 13 | 12 | |
| Current EPS | ($0.588) | ($2.291) | ($2.427) | |
| Month Ago EPS | ($0.592) | ($2.311) | ($2.479) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.558) | ($2.125) | ($2.120) | |
| Year/Year Chg | (9.0%) | (5.8%) | (41.5%) | |
| Financials | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($254) | ($44) | 5% |
|
| EPS (TTM) | ($2.485) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($209) | ($34) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $74 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $2,486 | $177 | 52% |
|
| Valuation | IMNM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.22 | 2.33 | 76% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMNM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (59.0%) | (47.6%) | 10% |
|
| ROE | (64.0%) | (54.9%) | 13% |
|
| Liabilities to Assets | 7.1% | 29.3% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Immunome, Inc. did not pass any screens on 10/9/2026.
